Published in Arch Virol on January 01, 1994
Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. J Proteome Res (2008) 1.73
Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelope. PLoS Comput Biol (2006) 1.25
Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies. J Virol (2012) 0.81
DNA sequence required for initiation of transcription in vitro from the major late promoter of adenovirus 2. Proc Natl Acad Sci U S A (1981) 9.08
Climate change. Recent reductions in China's greenhouse gas emissions. Science (2001) 5.77
Climate forcing by anthropogenic aerosols. Science (1992) 5.67
Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (1991) 5.42
Ecology. The value of nature and the nature of value. Science (2000) 5.32
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng (1989) 3.31
Amplification of surface temperature trends and variability in the tropical atmosphere. Science (2005) 2.99
Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees. Nature (1987) 2.82
Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J Virol (1997) 2.81
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Optimizing the exercise protocol for cardiopulmonary assessment. J Appl Physiol Respir Environ Exerc Physiol (1983) 2.76
Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol (1990) 2.58
Predicted values for clinical exercise testing. Am Rev Respir Dis (1984) 2.58
Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies. J Acquir Immune Defic Syndr (1992) 2.29
Chemical and enzymatic biotin-labeling of oligodeoxyribonucleotides. Nucleic Acids Res (1985) 2.29
Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation (2001) 2.28
Carbon dioxide pressure-concentration relationship in arterial and mixed venous blood during exercise. J Appl Physiol (1985) (2001) 2.26
Diet and flight hypoxemia. Ann Intern Med (1989) 2.02
Effects of obesity on respiratory function. Am Rev Respir Dis (1983) 1.99
Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature (1986) 1.98
Effect of acetazolamide on acute mountain sickness. N Engl J Med (1968) 1.98
Asparagine-linked glycosylation of the scrapie and cellular prion proteins. Arch Biochem Biophys (1989) 1.96
An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis (1991) 1.90
Translational control of SV40 T antigen expressed from the adenovirus late promoter. Cell (1983) 1.90
Global analysis of transcription kinetics during competence development in Streptococcus pneumoniae using high density DNA arrays. Mol Microbiol (2000) 1.89
Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol Lett (1996) 1.87
O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins. Nucleic Acids Res (1999) 1.81
Prediction of O-glycosylation of mammalian proteins: specificity patterns of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase. Biochem J (1995) 1.81
Detection of cytomegalovirus DNA in serum correlates with clinical cytomegalovirus retinitis in AIDS. J Infect Dis (1994) 1.69
Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol (1987) 1.63
AIDS vaccine development. Science (1998) 1.62
Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci U S A (1993) 1.58
T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. Nature (1986) 1.55
O-glycosidic carbohydrate-peptide linkages of Herpes simplex virus glycoproteins. Arch Virol (1981) 1.53
Analysis of the sites of integration of viral DNA sequences in rat cells transformed by adenovirus 2 or SV40. Cold Spring Harb Symp Quant Biol (1980) 1.52
Greenhouse Effects due to Man-Mad Perturbations of Trace Gases. Science (1976) 1.50
Unusual lectin-binding properties of a herpes simplex virus type 1-specific glycoprotein. J Virol (1981) 1.48
Herpes simplex virus type-selective enzyme-linked immunosorbent assay with Helix pomatia lectin-purified antigens. J Clin Microbiol (1984) 1.48
Diagnostic accuracy of a rural live video telepathology system. Am J Surg Pathol (1997) 1.48
The thyroid function and size in healthy man during 3 weeks treatment with beta-adrenoceptor-antagonists. Horm Metab Res (1991) 1.47
Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A (1991) 1.47
Auditing hospital drug utilisation by means of defined daily doses per bed-day. A methodological study. Eur J Clin Pharmacol (1980) 1.46
Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology (1996) 1.45
Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nat Biotechnol (2000) 1.43
A gene fusion system for generating antibodies against short peptides. Gene (1987) 1.42
Polychlorinated biphenyls, 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (p,p'-DDT) and 1,1-dichloro-2,2-bis(p-chlorophenyl)-ethylene (p,p'-DDE) in human plasma related to fish consumption. Arch Environ Health (1995) 1.40
A prospective study of fatal occupational accidents -- relationship to sleeping difficulties and occupational factors. J Sleep Res (2002) 1.40
Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells. Virology (1992) 1.40
Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol (1998) 1.39
Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol (1985) (1997) 1.39
[Treatment of benign recurrent goiter]. Ugeskr Laeger (1994) 1.38
Ethnic differences in pulmonary function in healthy nonsmoking Asian-Americans and European-Americans. Am J Respir Crit Care Med (2000) 1.38
[False results on elevated triiodothyronine values in radioimmunoassay]. Ugeskr Laeger (1995) 1.37
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
[Episodic hypoxemia and coinciding ECG changes after acute myocardial infarction]. Ugeskr Laeger (1995) 1.37
Forced and unforced ocean temperature changes in Atlantic and Pacific tropical cyclogenesis regions. Proc Natl Acad Sci U S A (2006) 1.36
Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol (1994) 1.35
Prevalence of antibodies to herpes simplex virus in pregnant women in Stockholm in 1969, 1983 and 1989: implications for STD epidemiology. Int J STD AIDS (1994) 1.34
Monitoring and risk assessment by means of alkyl groups in hemoglobin in persons occupationally exposed to ethylene oxide. J Environ Pathol Toxicol (1979) 1.33
Food production, population growth, and the environment. Science (1998) 1.32
Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape. J Gen Virol (1993) 1.31
Stoichiometry of monoclonal antibody neutralization of T-cell line-adapted human immunodeficiency virus type 1. J Virol (1999) 1.29
Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol (1985) 1.29
Regulation of integration by coliphage lambda: activation of int transcription by the cII and cIII proteins. Virology (1979) 1.29
Both X chromosomes function before visible X-chromosome inactivation in female mouse embryos. Nature (1978) 1.27
X-chromosome inactivation during differentiation of female teratocarcinoma stem cells in vitro. Nature (1978) 1.27
An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol (1996) 1.26
Relation of oxygen uptake to work rate in normal men and men with circulatory disorders. Am J Cardiol (1987) 1.25
Mosaics of gene variations in the Interleukin-10 gene promoter affect interleukin-10 production depending on the stimulation used. Genes Immun (2004) 1.25
Low cancer rates among patients with Parkinson's disease. Ann Neurol (1985) 1.24
Isolation of mouse x-chromosome specific DNA from an x-enriched lambda phage library derived from flow sorted chromosomes. Cytometry (1982) 1.24
Tanning habits and sunburn in a Swedish population age 13-50 years. Eur J Cancer (2001) 1.23
Candidate vaccines protect macaques against primate immunodeficiency viruses. AIDS Res Hum Retroviruses (1998) 1.22
Mutational analysis of the interaction between staphylococcal protein A and human IgG1. Protein Eng (1993) 1.22
A systematic error in the determination of blood PCO2. Am Rev Respir Dis (1977) 1.21
The genome of Shope fibroma virus, a tumorigenic poxvirus, contains a growth factor gene with sequence similarity to those encoding epidermal growth factor and transforming growth factor alpha. Mol Cell Biol (1987) 1.19
Expression of the human immunodeficiency virus gag gene in insect cells. Virology (1987) 1.19
Mental disorders after abortion. Acta Psychiatr Scand (1965) 1.18
Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol (1992) 1.18
Coxarthrosis and farm work: a case-referent study. Am J Ind Med (1997) 1.17
Evaluation of solubilized herpes simplex virus membrane antigens in diffusion in gel-enzyme-linked immunosorbent assay (DIG-ELISA). J Virol Methods (1982) 1.16
Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses (1997) 1.15
Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.15
Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance. Scand J Infect Dis (1998) 1.14
Characterization of a herpes simplex virus type 2-specified glycoprotein with affinity for N-acetylgalactosamine-specific lectins and its identification as g92K or gG. J Gen Virol (1986) 1.14
Carbohydrate determinant NeuAc-Gal beta (1-4) of N-linked glycans modulates the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J Gen Virol (1992) 1.13